Curevo's CEO describes P2 data released this week showing that amezosvatein may have a better profile than Shingrix

blonca9
Jan 11, 2024
1 min read

George Simeon explains how the 876-participant study showed non-inferiority vs Shingrix and lower rates of solicited local and systemic adverse events.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Curevo's CEO describes P2 data released this week showing that amezosvatein may have a better profile than Shingrix

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight